Category: Legislative

U.S. Senate Democrats are hopeful that drug pricing legislation will be passed by early next month via a budget reconciliation process requiring just 50 Democratic votes, a Democratic source with knowledge of the process told 340B Report.

“Our expectation is, we’re

A U.S. House Republican task force assigned to develop proposals the party can advance if the GOP takes the majority in the November elections apparently chose not to make recommendations for the 340B program.

The Healthy Future Task Force’s affordability

U.S. Senate Democrats’ revamped drug pricing legislation would lower the federal deficit by $287 billion over 10 years, the nonpartisan Congressional Budget Office said late last week.

Last November, CBO estimated that drug pricing language in the House-passed Build Back

If Congress votes to gives Medicare the power to negotiate some drug prices, drug manufacturers would not have to provide price concessions that exceed the lower of a drug’s 340B price or the Medicare negotiated price, according to a summary

The U.S. Office of Pharmacy Affairs (OPA), the department within the U.S Health and Resources Administration that oversees the 340B program, would receive a $2 million increase in funding under a bill that passed through a major House committee last

Drug manufacturers’ decisions to impose conditions on 340B pricing when covered entities use contract pharmacies “need to be addressed moving forward,” U.S. Rep. Debbie Dingell (D-Mich.) said last week during an Energy & Commerce (E&C) health subcommittee hearing last week.

The U.S. House Appropriations Committee said this week it is concerned about the growing number of drug manufacturers “that curtail the use of 340B drugs in contract pharmacies.” It encouraged the U.S. Health Resources and Services Administration to use “any